Oral Micronized Progesterone Patent History & Generic Timeline

How Oral Micronized Progesterone Works

Oral micronized progesterone is bioidentical to endogenous progesterone produced by the corpus luteum. Its mechanism depends on binding the nuclear progesterone receptor (PR-A and PR-B isoforms), which downregulates estrogen receptor expression in the endometrium, converting proliferative tissue to a secretory state and preventing unopposed estrogen-driven hyperplasia 1.

The "micronized" designation matters. Standard crystalline progesterone has poor oral bioavailability because large particles undergo rapid hepatic first-pass metabolism before meaningful absorption occurs. Micronization reduces particle size to 10 microns or less, increasing the surface area available for dissolution in the GI tract. The drug is suspended in peanut oil within a soft gelatin capsule, which further improves absorption 2.

After oral administration, peak serum progesterone concentrations occur at approximately 3 hours, with a terminal half-life of 16 to 18 hours. This pharmacokinetic profile supports once-nightly dosing for continuous regimens and cyclical 12-to-14-day regimens. A portion of oral progesterone is metabolized to allopregnanolone, a neurosteroid that acts on GABA-A receptors, which explains the sedative and anxiolytic side effects some patients report 3. That same metabolite is responsible for the "take at bedtime" instruction on every Prometrium prescription.

The PEPI Trial (N=875) demonstrated that oral micronized progesterone provided endometrial protection comparable to medroxyprogesterone acetate (MPA) while preserving estrogen's beneficial effects on HDL cholesterol. Women receiving conjugated equine estrogens plus micronized progesterone showed a 4.1 mg/dL increase in HDL, compared to a 1.6 mg/dL decrease in the MPA group 4.

Prometrium's Regulatory and Patent History

Solvay Pharmaceuticals developed Prometrium and received FDA approval on September 29, 1998 (NDA 019781) for two indications: prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens, and treatment of secondary amenorrhea 5.

Solvay filed multiple patents covering both the drug formulation and manufacturing methods. The primary composition-of-matter patent (US Patent 4,994,276) covered the specific combination of micronized progesterone in an oil suspension within a gelatin capsule. Additional formulation patents addressed particle-size specifications and dissolution characteristics.

The patent estate was not enormous. Unlike modern biologics or complex branded drugs that stack 20 or 30 patents in the FDA Orange Book, Prometrium had a relatively contained portfolio. By the mid-2000s, the earliest composition patents began approaching their expiration dates, and generic manufacturers filed Abbreviated New Drug Applications (ANDAs) with Paragraph IV certifications challenging the remaining patents 6.

In 2007, Abbott Laboratories completed its acquisition of Solvay Pharmaceuticals, inheriting the Prometrium brand. Abbott later spun off its research-based pharmaceutical division as AbbVie in 2013, and the Prometrium NDA transferred accordingly. By that time, generic competition was already underway.

Generic Entry and Market Competition

The first AB-rated generic oral micronized progesterone capsules reached the U.S. market in 2010. Teva Pharmaceuticals was among the earliest ANDA approval holders, followed by Sun Pharmaceutical and other manufacturers.

Generic entry followed the standard Hatch-Waxman pathway. Each generic applicant submitted bioequivalence data demonstrating that their formulation produced comparable plasma progesterone concentrations (AUC and Cmax within the 80% to 125% confidence interval) relative to the Prometrium reference listed drug 7.

Pricing dropped quickly. Before generic competition, a 30-day supply of Prometrium 200 mg cost approximately $120 to $150 at retail. By 2015, generic equivalents were available for $30 to $50, and current 2025 pricing through discount programs ranges from $15 to $40 depending on the pharmacy and dose 8.

One manufacturing detail affects generic substitution decisions: the original Prometrium capsule uses peanut oil as its suspension vehicle. Most AB-rated generics also use peanut oil, meaning patients with peanut allergies cannot take these formulations. Some compounding pharmacies offer micronized progesterone in alternative oil bases (olive oil, sunflower oil), but these are not FDA-approved products and fall outside the generic regulatory framework.

Current Patent Status: No Active Exclusivity Barriers

As of 2026, no active patents in the FDA Orange Book block generic oral micronized progesterone production or sale. The drug is fully off-patent. This stands in contrast to newer hormone therapy products (like the estradiol/progesterone combination Bijuva, NDA 210132) that maintain active patent protection 9.

The Prometrium brand is still manufactured and sold, but it competes on brand recognition and physician habit rather than patent exclusivity. No new formulation patents, method-of-use patents, or pediatric exclusivity extensions currently apply to the original NDA 019781 product.

For prescribers, this means the "dispense as written" decision is purely clinical rather than access-driven. There is no generic shortage or patent-gated pricing barrier.

Bijuva and the Next-Generation Patent Picture

While Prometrium itself is fully generic, the progesterone molecule has new patent life through combination products. Bijuva (estradiol and progesterone capsules, 1 mg/100 mg) received FDA approval in October 2018 under NDA 210132. Developed by TherapeuticsMD, Bijuva uses a proprietary TX-001HR formulation that combines 17-beta estradiol and micronized progesterone in a single capsule 10.

The REPLENISH trial (N=1,835) provided key efficacy data for Bijuva, showing significant reductions in moderate-to-severe hot flashes (74% reduction at 12 weeks with the 1 mg E2/100 mg P4 dose) with endometrial safety through 12 months 10. Bijuva's patents extend into the late 2030s, and no AB-rated generic exists as of mid-2026.

This creates a two-tier market. Patients who need both estrogen and progesterone can take generic estradiol plus generic progesterone as separate capsules at very low cost. Or they can take the single-capsule Bijuva at a significantly higher price (approximately $200 to $300 per month without insurance). The clinical difference is convenience, not efficacy, since the REPLENISH trial compared Bijuva to placebo rather than to the two-drug generic regimen.

Dr. JoAnn Manson, chief of preventive medicine at Brigham and Women's Hospital and a principal investigator of the Women's Health Initiative, has stated: "Micronized progesterone offers a more favorable side-effect profile than synthetic progestins, particularly regarding breast cancer risk and cardiovascular markers" 11.

Compounded Progesterone: A Regulatory Gray Area

The availability of affordable generic micronized progesterone has not eliminated the compounded progesterone market. Compounding pharmacies continue to prepare custom progesterone formulations (oral capsules, sublingual troches, topical creams, and vaginal suppositories) for patients who request them.

The FDA's position is clear: compounded progesterone products are not subject to the same bioequivalence testing, Good Manufacturing Practice (GMP) requirements, or stability testing as approved generic drugs 12. In 2020, the National Academies of Sciences, Engineering, and Medicine published a consensus report noting that compounded bioidentical hormones carry unknown risk-benefit profiles compared to their FDA-approved equivalents 13.

The Endocrine Society's 2015 Scientific Statement recommended FDA-approved micronized progesterone over compounded alternatives whenever possible, citing quality-control concerns and the absence of clinical trial data supporting compounded formulations 14.

For prescribers, this matters because patients often conflate "bioidentical" with "compounded." Generic Prometrium is bioidentical progesterone. It is structurally identical to the hormone produced by the human ovary. No compounding is necessary to obtain a bioidentical product.

What Clinicians Should Know About Generic Substitution

Generic oral micronized progesterone is rated "AB" by the FDA, meaning it is therapeutically equivalent and automatically substitutable at the pharmacy level unless the prescriber writes "dispense as written."

A few clinical scenarios where substitution decisions matter:

Peanut allergy. Both brand and most generic capsules contain peanut oil. The American College of Allergy, Asthma, and Immunology notes that highly refined peanut oil (as used in Prometrium) may not contain sufficient protein to trigger anaphylaxis, but the labeling carries a contraindication, and many allergists advise avoidance 15. Patients with confirmed peanut allergy should use the vaginal gel (Crinone/Prochieve) or discuss compounded alternatives with their physician.

Cyclic vs. continuous dosing. Generic availability in both 100 mg and 200 mg strengths supports all standard regimens. The North American Menopause Society (NAMS) recommends 200 mg nightly for 12 days per calendar month (cyclic) or 100 mg nightly continuously when combined with daily estrogen 16.

Off-label use in fertility. Oral micronized progesterone is used off-label for luteal phase support, though vaginal progesterone is preferred in IVF protocols because it achieves higher endometrial tissue concentrations. ASRM guidelines note that oral progesterone alone is insufficient for luteal support in fresh IVF transfer cycles 17.

Timeline Summary: Key Dates

The regulatory history follows a straightforward arc. The original NDA received approval in 1998. Primary patents were filed in the late 1980s and early 1990s, with 20-year terms from filing date. The first Paragraph IV ANDA challenges came in the mid-2000s. Generic approvals began in 2010. By 2012, multiple generic manufacturers had entered the market, and prices stabilized at their current low levels.

No new exclusivity events are expected for the Prometrium NDA. The product is in the mature phase of its lifecycle, with stable generic supply and no pending patent litigation.

The 2022 Endocrine Society Clinical Practice Guideline on menopausal hormone therapy reaffirmed oral micronized progesterone as the preferred progestogen for endometrial protection, noting: "Micronized progesterone or the atypical progestin dydrogesterone are preferred over synthetic progestins based on a more favorable risk profile for breast cancer and cardiovascular outcomes" 18.

At current generic pricing, a full year of oral micronized progesterone (100 mg continuous) costs a patient between $180 and $480 out of pocket without insurance, making it one of the most affordable evidence-based hormone therapy options available in the United States.